Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): AST2303 tablets receive approval for drug clinical trials.

17:42 23/09/2024

Ails (688578.SH) announced recently that the company has received the approval and issuance of the "Drug Clinical ..." by the National Medical Products Administration.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFR C797S mutation. The announcement states that AST2303 tablets (ABK3376 tablets) are a highly selective and brain-permeable new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.

The digital payment industry is facing a severe test. Goldman Sachs Group, Inc. downgraded PayPal (PYPL.US) rating to "sell".

Optimization of call routing business Iconectiv significantly increased Telefonaktiebolaget LM Ericsson Sponsored ADR Class B (ERIC.US) Q3 profit doubled.

CMSC maintains a "strong buy" rating on JD-SW (09618) and remains optimistic about the company's growth resilience and profit improvement potential in the long term.

The digital payment industry is facing a severe test. Goldman Sachs Group, Inc. downgraded PayPal (PYPL.US) rating to "sell".

Optimization of call routing business Iconectiv significantly increased Telefonaktiebolaget LM Ericsson Sponsored ADR Class B (ERIC.US) Q3 profit doubled.

CMSC maintains a "strong buy" rating on JD-SW (09618) and remains optimistic about the company's growth resilience and profit improvement potential in the long term.